MedTrace Logo

Ovarian Stimulation With Recombinant Gonadotropins vs. Human Menopausal Gonadotropin in In Vitro Fertilization

NCT02322398 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 848

Last updated 2014-12-23

No results posted yet for this study

Summary

The purpose of this retrospective study was to assess the outcome of In Vitro Fertilization (IVF) according to the type of medication used for controlled ovarian stimulation (COS). The study compared the pregnancy rate obtained by 398 patients who had received COS with recombinant Follicle Stimulating Hormone (rFSH) plus recombinant Luteinising Hormone (rLH) in 2:1 ratio vs. the one observed in 450 patients who had been treated with human Menopausal Gonadotropin (hMG), stratifying results according to the number of retrieved oocytes.

Conditions

Interventions

DRUG

rFSH plus rLH

150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio

DRUG

hMG

150-300 IU/d hMG

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Principal Investigators

  • Alberto Revelli, MD PhD · Physiopathology of Reproduction and IVF Unit, S. Anna Hospital

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02322398 on ClinicalTrials.gov